FDA Approves IMULDOSA® (ustekinumab-srlf), Accord BioPharma's Biosimilar to STELARA® (ustekinumab), for the Treatment of Chronic Inflammatory Conditions

Oct 14, 2024

Ahmedabad (Gujarat) [India], October 14: Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and...

Accord Healthcare receives positive CHMP opinion for IMULDOSA®, ustekinumab biosimilar to Stelara®

Oct 19, 2024

Ahmedabad (Gujarat) [India], October 19: Accord Healthcare Limited (Accord) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

European Medicine Agency accepts Intas' Marketing Authorization Application for DMB-3115, a Proposed Biosimilar to Stelara (Ustekinumab)

Jul 14, 2023

Ahmedabad (Gujarat) [India], July 14: Intas Pharmaceuticals Ltd. announced that the European Medicine Agency (EMA) confirms acceptance of the Marketing Authorization Application (MAA) for...

Prestige Biopharma's Herceptin Biosimilar Tuznue® Receives Positive CHMP Opinion from the EMA

Aug 01, 2024

Singapore, August 1: Prestige Biopharma, a pioneer in biopharmaceuticals, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Biocon Biologics partners with IDF to promote diabetes care

Feb 16, 2021

Bengaluru (Karnataka) [India], February 16 : Biocon Biologics has partnered with the International Diabetes Federation (IDF) as the first biosimilar insulin company to promote...

EMA approves Biocon Biologics' new monoclonal antibodies facility, renews GMP certifications for India and Malaysia sites

Jun 24, 2024

According to a press release, this facility, designed to produce multiple drug substances, will now commence the production of biosimilar Bevacizumab, enhancing the company's...